March 09, 2016 – – BloodThinnerHelp.com reports on an overview of the now more than 3,300 Xarelto lawsuits which have been filed since 2011 alone. The U.S. Food and Drug Administration approved the new-generation, blood-thinning drug in 2011 to treat patients recovering from hip and knee replacement surgeries, suffering from deep vein thrombosis and pulmonary embolism, or atrial fibrillation. The drug was long-awaited and launched onto the market as a revolutionary new anticoagulant which provided those requiring the use of blood thinners with new freedoms that traditional blood thinners hadn’t offered.

Since that time, however, more than 3,300 Xarelto lawsuits have been filed by plaintiffs from across the nation, alleging that the drug poses significant risks to users; most notably sudden bleeding episodes. The lawsuits filed have been consolidated into two major groups. In the Eastern District of Louisiana, the U.S. Judicial Panel on Multidistrict Consolidation transferred federally-filed Xarelto cases to one court. Here they have become MDL No. 2592, and are being overseen by the Honorable Judge Eldon Fallon. These cases number over 2,800 at this time, and are joined by more than 600 others which were consolidated in Philadelphia, Pennsylvania to form a mass tort group by the Court of Common Pleas.

Xarelto lawsuits in MDL 2592 are scheduled for bellwether trials, which are said to take place near the beginning of 2017. At this time, bellwether trial dates have been set for February 6, April 24, and May 30 of 2017. Plaintiffs involved in all of the Xarelto lawsuits share strikingly similar allegations and have filed their complaints against the same defendants: Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson).

Recently, Xarelto has been the subject of even more controversy, however, as the European Regulators announced that they would be conducting an investigation into faulty testing equipment used during clinical trials on the drug, which may have led to its premature FDA approval. In addition, many are currently questioning whether manufacturers left out important information during the FDA approval process; some allege that this information was purposefully excluded.

As Xarelto lawsuit numbers continue to grow and additional investigations are done regarding the drug, Attorney Joseph Osborne is working to help ensure that anyone who feels they may have been harmed by the drug will also be given the important opportunity of exploring their legal rights in full. These individuals and their families may be entitled to legal action and substantial compensation. To better assist those wishing to pursue justice, Attorney Osborne is offering free legal consultations at this time for affected parties.

To ask questions or request additional Xarelto lawsuit information, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008594

March 09, 2016 – – TheProductLawyers.com reports on the latest news surrounding new-generation, type-2 diabetes drug Invokana. Since its 2013 FDA approval, the drug has now become the subject of several lawsuits linking it to various health problems, including cardiovascular damage and kidney failure in patients.

Invokana works to maintain blood sugar (glucose) levels in type-2 diabetes patients, and it does this by preventing the kidneys from absorbing any extra sugar and instead forcing them to remove the sugar from the body via urination. This process understandably depends heavily on the kidneys, and, therefore, puts substantial stress on them. As kidney problems can be common in diabetic patients even without the medication, those with pre-existing kidney problems should be especially aware of this potential danger.

On December 15 of 2015 in a Southern Alabama District Court, a plaintiff filed a lawsuit against Invokana manufacturer Janssen Pharmaceuticals (a division of pharmaceutical giant Johnson & Johnson). The lawsuit details state that the plaintiff had used the drug without being previously made aware of the serious and dangerous side effects possible. She indicates that she used the drug for only a short time when she suddenly developed diabetic ketoacidosis, a potentially life-threatening condition in which the body’s bloodstream contains too much toxic acid.

The plaintiff believes that the defendant showed negligence by not making the public and medical professionals better aware of these serious risks, and by neglecting to adequately study and vet the drug before releasing it to market after approval by the U.S. Food and Drug Administration in 2013. In addition, she notes that she was taking the drug to treat her type-1 diabetes, as it had been promoted “off-label” for this use. “Off-label” means that this use was never FDA-approved, but was advertised by the manufacturer: a very controversial marketing move.

In 2013, Invokana was the first of several similar new-generations drugs which were released for diabetes patients; all members of the SGLT2 inhibitor class. Although adverse event reports to the FDA have now been made surrounding all of these drugs, Invokana is the drug most commonly discussed by patients.

The attorneys of Banville Law are dedicated to keeping the public informed of the dangers associated with Invokana and Invokana lawsuit news. They sponsor the online resource website TheProductLawyers.com and work to help ensure that anyone who has taken Invokana and feels that they suffered from health problems due to the drug will be given the opportunity to evaluate their legal options in full. These patients may be eligible for legal action and substantial compensation. To help those looking to seek justice, the attorneys of Banville Law are currently offering free Invokana consultations for qualified parties.

To request additional information on Invokana lawsuits, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008595

March 09, 2016 – – BloodThinnerHelp.com announces the details of another Xarelto-based lawsuit which was filed against pharmaceutical manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), in addition to several other defendants. The lawsuit discusses new-generation anticoagulant drug Xarelto, and potentially dangerous side effects. Allegations made by the plaintiff within the complaint indicate that the blood-thinning drug caused him to suffer from a sudden and dangerous bleeding episode. After its initial filing, the complaint was transferred with all federally-filed Xarelto lawsuits by the U.S. Judicial Panel on Multidistrict Litigation. This consolidation placed more than 2,800 cases in a single court to fast track the litigation. Cases are now a part of MDL No. 2592 in New Orleans, Louisiana. The Honorable Judge Eldon E. Fallon is presiding over all involved cases.

This lawsuit is sure to stand out, even among 2,800 others, due to the fact that it involves 90-counts. In addition, the filing plaintiff has requested a large sum of $4.35 million in compensation. He claims that defendants Bayer AG and Janssen (Johnson & Johnson) marketed Xarelto in misleading ways in order to display it as a safe and effective treatment for patients, and also failed to adequately discuss potential dangerous side effects linked to the drug.

In further details of the suit, the plaintiff also claims that manufacturers were likely aware that the anticoagulant may cause increased bleeding risks for patients taking it. Results from several clinical studies completed on the drug, and also several medical studies conducted on it seem to lend support to this argument. The plaintiff stated, “Defendants use the results of the Rocket AF study, the Record studies, and the Einstein studies to promote Xarelto in their promotional materials, including the Xarelto website, which tout the positive results of those studies. However, defendants’ promotional materials fail to similarly highlight the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”

Previous reports have indicated that Xarelto manufacturers likely spent more than $11 million to promote Xarelto with detailed advertisements, many of which utilized the endorsements of famous sports icons and celebrities. The ads brought in an estimated $582 million in revenue through Xarelto sales during the drug’s first year on the market alone.

Attorney Joseph Osborne is working to help ensure that everyone who believes they may have suffered health problems from using Xarelto will be given the important opportunity to fully investigate their legal rights. These patients and their families may be entitled to significant compensation. To better assist those looking to pursue justice, Attorney Osborne is currently offering complimentary Xarelto consultations for those who qualify.

To request more Xarelto bleeding lawsuit information, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008596

March 09, 2016 – – Torrid Technologies, Inc., a company based out of Marietta, Georgia, has recently released the 2016 version of their award-winning Retirement View software for Mac computers. The new version includes all of the award-winning capabilities of its predecessor, with some additional improvements. The software has been in circulation and consistently updated since 1994 when it first appeared for the Mac operating system.

The software was designed to help you plan your retirement, and also for use by financial advisors to create visual retirement plans for their clients. Torrid Technologies founder Tim Turner says, “The RetirementView software can be used by just about anyone to build a retirement plan, even if you aren’t that good with a computer. It’s more robust than free internet calculators and way easier to use than most complicated software systems.”

Currently, Torrid Tech is providing access to a free demo of the software from the company’s website at http://www.torrid-tech.com. The tool is described as being easy to use, easy to learn, and uses a simple fill-in-the-blank system. It works quickly, processing accurate retirement saving plans in less than 15 minutes.

The Retirement View software for Maccan be downloaded directly from the Torrid Technologies site for both individuals and financial advisors. From there, potential users of the software can read the reviews of current customers, speak to a member of the team or view other products and services offered through the company.

A unique video tour of the capabilities of the 2016 software release is also available through the website, providing some insight into the upgrades and additional content which users can benefit from during the retirement planning process. This walks users through entering data such as Social Security, Pensions, investments, benefits, special expenses, and other cash disbursements. It also shows why using a basic online calculator for this type of planning is inefficient.

Price varies between the personal edition, couple’s edition, and professional edition, but both offer the same colorful graphics, real-time experience, and uncomplicated process to provide users with effortless planning potential. The company invites interested parties to download the trial version and see for themselves how easy it is to build your own retirement plan and take control over your retirement finances.

RetirementView software is available on both Mac and Windows computers, as well as tablets. Consumers use it for do-it-yourself retirement planning for both workers and those already retired. Financial advisors use RetirementView to build retirement plans for clients that they can see and discuss changes to avoid running out of money.

###

Contact Torrid Technologies, Inc.:

Miji Pearse
770-884-6085
miji@torrid-tech.com
1860 Sandy Plains Rd Ste 204-129
Marietta, GA 30066

ReleaseID: 60008588

March 09, 2016 – – TheProductLawyers.com announces recent reports of 101 patient cases of diabetic ketoacidosis which have been linked to their use of Invokana and other SGLT2 inhibitor drugs according to a safety warning issued by the European Medicines Agency. There are multiple brands of SGLT2 inhibitors available to consumers at this time, however, Invokana was the first of the new-generation diabetes medications to be released.

SGLT2 is an abbreviation for sodium-glucose cotransporter-2 drugs. The drugs in this category work by controlling blood glucose (sugar) levels for diabetic patients by removing excess sugar from the body through urination. EMA’s most recent report also notes that over 500,000 diabetic patients have now used SGLT2 class inhibitors since March, 2013 when they were initially released to market.

Ketoacidosis is a potentially life-threatening condition in which the body produces too many ketones, causing the bloodstream to contain too much toxic acid. The condition can appear in as little as 24 hours and, if it remains undiagnosed, can cause patients to enter a coma or die.

The EMA’s warning stated, “Although diabetic ketoacidosis is usually accompanied by high blood sugar levels, in a number of these reports blood sugar levels were only moderately increased. These uncharacteristic blood levels could delay diagnosis and treatment.” Because of this trouble with diagnosing such a serious and even deadly ketoacidosis condition, many medical professionals are requesting that those currently using SGLT2 inhibitors remain extra aware of any indicators that the body may be developing ketoacidosis.

According to the U.S. Food and Drug Administration (FDA) they have also received reports of ketoacidosis cases which were connected to patient’s use of several SGLT2 inhibitor drugs within only their first year on the market. SGLT2 drugs mentioned in the FDA reports include: Invokana, Invokamet, Glyxambi, Farxiga, Jardiance, and Xigduo XR.

The attorneys of Banville Law, who sponsor online resource website TheProductLawyers.com, understand the seriousness of ketoacidosis conditions, and they understand how important it is for diabetes patients to obtain safe and effective treatments. They are now working to help ensure that everyone who took SGLT2 class drugs and who suffered from health problems which they attribute to the drugs will be provided the important opportunity to evaluate their legal rights in full. Banville Law is currently offering complimentary legal consultations to affected parties at this time. These individuals may be entitled to significant compensation.

To obtain additional information on Invokana, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008587

The Multi-Specialty Dental Practice Now Has Six Clinics Serving the GTA

Toronto, ON – Martindale Dental, a multi-specialty dental practice, has opened its flagship location in Toronto’s downtown fashion district.  The dental practice has witnessed rapid growth occurring in the King St. West area and has jumped on the opportunity to become a part of the community.

A partner at Martindale Dental, Dr. Balaji Swaminath, celebrates the “coming-to-fruition” of his long-time dream. “Ever since we opened our first location 20 years ago, it has been my dream to see a Martindale Dental practice in every corner of the GTA.  I am extremely pleased to announce that our practice can now serve the King St. West community for all dental health needs.”

In order to be in a situation where adding an office location was possible, Martindale Dental has been proving itself again and again with excellent customer service and the motto that “Everyone deserves a healthy smile”.  Martindale Dental has become the premier dentist in cities Milton, Burlington and St. Catharines and will be taking its recipe for success to downtown Toronto.  The newly launched King St. West location will be headed by Dr. Ranu, and will be focused on providing dental care for your whole family.

About Martindale Dental:

Martindale Dental is a premiere provider of general, specialty and cosmetic dentistry for the whole family.  Practices are located throughout the GTA in St. Catharines, Burlington, Milton and Toronto.  Boasting over 20 years of dental experience, the practitioners at Martindale Dental are committed to providing the best level of customer service to go along with their promise of complete dental care.

Media Contact
Company Name: Martindale Dental
Contact Person: Dr. Balaji Swaminath
Email: info@martindaledental.com
Phone: (888) 744-0791
Address:100 Martindale Rd.
City: St. Catherines
State: ON
Country: Canada
Website: http://martindaledental.com/

Source: ABNewswire

ReleaseID: 55364

According to the founder of the Manufacturing Media Consortium, Thomas R. Cutler, one of the more intriguing automation trends of the past few years has been the rapid development and introduction on new robotics technologies. Much of this trend has been driven by the rise of collaborative capabilities—meaning these robots can work alongside humans rather than in secure areas or cages.

This trend seems to be gathering enough speed now to affect both collaborative and non-collaborative robotics—as can be seen in the recent introduction of goods to person technologies.  MODEX 2016 will be held April 4 – 7, 2016 in Atlanta and as the largest Material Handling event of the year will illustrate these new collaborative trends.

About TR Cutler, Inc. 

TR Cutler, Inc. was founded seventeen years ago by Thomas R. Cutler. Cutler maintains extraordinary relationships with clients, journalists, editors, economists, trendsetters, and key business leaders worldwide and has become a key resource for those writing about the manufacturing sector.

Cutler founded the Manufacturing Media Consortium in 1999, which now has more than 6,000 global members including journalists, editors, publishers, and economists, worldwide writing about trends, industrial data, manufacturing case studies, material handling profiles, and robotics feature articles.  Cutler works with thousands of media outlets to expand the coverage and importance of the manufacturing media coverage.

Cutler has authored more than 5,000 articles for a wide range of manufacturing periodicals, industrial publications, and business journals each published in leading monthly trade magazines, B2B periodicals, blogs, and marquis publications globally. Cutler is the host of a new weekly episodic video program called Kanbanversation. He is also the President and CEO of Fort Lauderdale, Florida-based, TR Cutler, Inc., (www.trcutlerinc.com), the largest manufacturing communication firm worldwide with four dozen of industry experts and thought leaders on staff. 

Cutler is the most published freelance industrial journalist worldwide, and thousands follow Cutler on Twitter daily at @thomasrcutler

Media Contact
Company Name: TR Cutler Inc.
Contact Person: Thomas R. Cutler
Email: trcutler@trcutlerinc.com
Phone: 954-682-6200
Address:3032 S. Oakland Forest Dr. S-2803
City: Fort Lauderdale
State: FLORIDA
Country: United States
Website: http://www.trcutlerinc.com

Source: ABNewswire

ReleaseID: 55359